Cargando…

Immune checkpoint inhibitors for first‐line treatment of advanced non‐small‐cell lung cancer: A systematic review and network meta‐analysis

OBJECTIVE: Currently, several immune checkpoint inhibitors (ICIs) treatment for advanced non‐small‐cell lung cancer (NSCLC) have been investigated; their overall efficacy and safety remain unclear. METHODS: We searched electronic databases such as PubMed, EMBASE, and the Cochrane library. The random...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Tzu‐Rong, Lin, Hung‐Hong, Tsai, Fang‐Pei, Wu, Ta‐Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563153/ https://www.ncbi.nlm.nih.gov/pubmed/34545685 http://dx.doi.org/10.1111/1759-7714.14148

Ejemplares similares

Intracranial activity of first-line immune checkpoint inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Huang, Zhe, et al.
Publicado: (2023)

Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Chen, Yuqiao, et al.
Publicado: (2019)

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
por: Kuo, Chih‐Hsi Scott, et al.
Publicado: (2019)

Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer
por: Xu, Manyi, et al.
Publicado: (2023)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis
por: Cao, Rui, et al.
Publicado: (2019)

Comparative efficacy and safety of first‐line treatments for advanced non‐small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta‐analysis
por: Chen, Rui, et al.
Publicado: (2019)

Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis
por: Kim, Jinchul, et al.
Publicado: (2022)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

Advances in immune checkpoint inhibitors therapy for small cell lung cancer
por: Li, Longhui, et al.
Publicado: (2023)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors
por: Deng, Jiayi, et al.
Publicado: (2022)

Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
por: Chen, Hsiao-Ling, et al.
Publicado: (2020)

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
por: Addeo, Alfredo, et al.
Publicado: (2019)

A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer
por: Shao, Taihang, et al.
Publicado: (2022)

Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer
por: Stares, M., et al.
Publicado: (2022)

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
por: Ortega-Franco, A., et al.
Publicado: (2021)

Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
por: Altaf, Reem, et al.
Publicado: (2022)

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer
por: Li, Ying, et al.
Publicado: (2022)

Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis
por: Liu, Tingting, et al.
Publicado: (2023)

Patterns of Failure in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Chai, Rong, et al.
Publicado: (2021)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50%
por: Chen, Wei, et al.
Publicado: (2023)

Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’
por: Takada, K., et al.
Publicado: (2022)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with advanced non‐small cell lung cancer: A meta‐analysis of randomized clinical trials
por: Peng, Tzu‐Rong, et al.
Publicado: (2019)

Efficacy and safety of anaplastic lymphoma kinase inhibitors for non–small cell lung cancer: A systematic review and network meta‐analysis
por: Peng, Tzu‐Rong, et al.
Publicado: (2023)

Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
por: Tun, Aung Myint, et al.
Publicado: (2019)

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
por: Pacheco, Jose M., et al.
Publicado: (2019)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer
por: Kehl, Kenneth L., et al.
Publicado: (2021)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
por: Kang, Shuo, et al.
Publicado: (2022)

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2018)

Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer
por: Fiorica, Francesco, et al.
Publicado: (2021)

Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis
por: Xu, Zexi, et al.
Publicado: (2021)

Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study
por: Wang, Qi, et al.
Publicado: (2023)

Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
por: Khan, Muhammad, et al.
Publicado: (2018)

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
por: Wang, Chengdi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_blflkeanr306fo761ieferu5qs